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Objectives. We sought to compare outcomes of patients treated
in the National Heart, Lung, and Blood Institute (NHLBI)
Percutaneous Transluminal Coronary Angioplasty (PTCA) and
New Approaches to Coronary Intervention (NACI) registries.
Background. Coronary angioplasty has numerous shortcom-
ings. New devices for performing coronary interventions have
been introduced in an effort to improve clinical outcomes.
Methods. Under the sponsorship of the NHLBI, a registry of
consecutive patients treated with PTCA during 1985 to 1986 was
established. In 1990, the NHLBI funded a second registry, the
NACI. The two registries used the same data coordinating center
to collect detailed baseline and follow-up information.
Results. Patients enrolled in the NACI registry were older, had
undergone more previous bypass surgery procedures and had
more stenoses located in bypass grafts than patients in the NHLBI
PTCA registry. Procedural success was achieved in 72.1% and
82.6% of patients in the PTCA and NACI registries, respectively;
however, in-hospital and 1-year mortality rates were 1.0% versus
1.8% and 3.1% versus 5.9% for the PTCA versus NACI registries,
respectively. After risk adjustment, there was no difference in
1-year mortality. Rates of target lesion revascularization (TLR)
were 21.5% for the PTCA registry and 24.2% for the NACI registry.
NACI registry patients had a higher risk for TLR and the
composite end point of death, myocardial infarction or revascu-
larization (relative risk 1.28 and 1.23, respectively). However, the
NACI registry patients who received stents tended to have a lower
adjusted TLR rate.
Conclusions. This comparative study found no overall superi-
ority of these newer devices in terms of patient survival or freedom
from TLR after adjustment for baseline risk profiles. Although
technologic improvements (especially improved stenting) con-
tinue, these observations highlight the importance of careful
assessment of clinical results in the broad population of patients
in whom interventions are used.
(J Am Coll Cardiol 1998;31:558–66)
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Multicenter registries of percutaneous coronary interventions
first came into being at the urging of Andreas Gruentzig and
others, under the sponsorship of the National Heart, Lung, and
Blood Institute (NHLBI), National Institutes of Health, Be-
thesda, Maryland. The first registry catalogued .3,000 consec-
utive patients undergoing percutaneous transluminal coronary
angioplasty (PTCA) between 1977 and 1981. After some
maturity of both the technique and technology, notably the
development of steerable guide wires, a new registry (PTCA
II) was sponsored by the NHLBI to enroll patients undergoing
initial PTCA in 1985 and 1986 (1).
With the advent of new devices in the late 1980s, a third
registry (New Approaches to Coronary Intervention [NACI])
of patients undergoing catheter-based interventions with these
new devices between 1990 and 1994 was established with the
assistance of the NHLBI (2). The existence of the PTCA II and
NACI registries allows for a comparison of balloon angioplasty
and new device angioplasty at a time when reasonable guide
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catheter and guide wire technology was available and each
method had achieved a modest degree of maturity.
Methods
Patient selection. A total of 2,431 patients from 16 centers
were enrolled in the PTCA II registry, and 4,389 patients from
39 clinical sites were enrolled in the NACI registry. To
facilitate comparisons, we focused on the elective use of
planned devices as much as possible, limiting the analysis to
patients not experiencing acute, evolving myocardial infarction
(MI). In PTCA II, there were 2,311 such consecutive patients
who underwent their first angioplasty. To make the NACI
cohort comparable to the PTCA II cohort, we excluded 527
patients who were later enrolled separately at the end of the
recruitment period, as well as those with a previous angioplasty
and patients who had new devices used as a rescue strategy
after failed angioplasty. Using these criteria, there were 1,985
patients in the NACI registry who had undergone procedures
involving directional coronary atherectomy (DCA [n 5 607]),
transluminal extraction catheter (TEC [n 5 255]), rotational
atherectomy (ROTA [n 5 228]), stents (n 5 182), lasers (n 5
581) and multiple new devices (n 5 132).
Definitions. Myocardial infarction was defined in the PTCA
II registry, as the presence of at least two of three criteria:
clinical symptoms, Q waves on the electrocardiogram (Minne-
sota Code) or elevated cardiac enzyme levels (double the
normal levels for creatine kinase or its MB fraction. However,
the individual criteria for detecting MI were not available for
events occurring after the index hospital period. In the NACI
registry, MI included the presence of Q waves (two-step Q
wave change defined by the Minnesota Code) and “other MI”
criteria (doubling of creatine kinase or its MB fraction without
Q waves). Angiographic success was defined as a reduction in
percent stenosis of at least 20% and a residual stenosis ,50%
in all attempted lesions. Procedural success was defined as
lesion success without in-hospital death, Q wave MI or coro-
nary artery bypass graft surgery (CABG). Target lesion revas-
cularization (TLR) was defined as either a repeat catheter-
based procedure in the segment treated at baseline or any
bypass surgery after hospital discharge for the original proce-
dure. Data collected and their definitions were similar between
the PTCA II and NACI registries, and the data coordinating
center was the same. Although angiographic core laboratories
provided readings for a subset of films in each registry, this
report uses site-reported assessments for data comparability
and completeness.
Follow-up assessment. Patients in both registries were
contacted by the site coordinator 1 year after their index
procedure. Information on vital status, hospital admission for
MI or repeat revascularization, symptoms, activity level, em-
ployment status and medication use was collected on standard
forms. In the PTCA II registry, patients reported the occur-
rence of angina during the 30 days before the interview;
patients in the NACI registry reported angina during the
previous 6 weeks. Lesion-specific information on repeat inter-
ventions was used to assess the outcome TLR.
Statistical analysis. Differences in proportions between
subgroups were assessed by chi-square test or Fisher exact test,
as appropriate. Differences in mean values of variables mea-
sured on a continuous scale were assessed by the Student t test;
for variables with excessively skewed distributions, median
values were compared using the Wilcoxon test. Life-table
analysis with the product-limit method (3) was used to estimate
event rates at 1 year. Cox regression analyses (4) were imple-
mented to estimate crude and adjusted relative risks of an
event for the NACI versus PTCA II registry. Baseline patient-
specific factors, including age, gender, history of MI, hyperten-
sion, diabetes, congestive heart failure, number of diseased
vessels, unstable angina, previous bypass surgery, severe, con-
comitant noncardiac disease and high surgical risk, were
considered for adjustment in models of morbid events and
repeat procedures. Also considered were baseline lesion fac-
tors, such as the presence of thrombus, calcium, eccentricity
and total occlusion in any attempted lesion. For models of
TLR, “vein graft attempt” was forced into each model, and
“number of lesions attempted” was also considered.
To address potential confounding factors due to different
centers and operators in the two registries, all comparisons are
supplemented by identical analyses using only the five sites
participating in both registries (Medical College of Virginia,
Mayo Clinic, Emory University, Miami Heart Institute and
Montreal Heart Institute).
Results
Baseline characteristics. Some of the numerous differ-
ences in patient baseline characteristics between the two
registries (Table 1) reflect the later time frame of the NACI
registry. NACI registry patients were 5 years older on average,
and three times as many had undergone a previous CABG and
had heart failure or severe concomitant disease. Diabetes was
more prevalent in the NACI registry. Baseline anginal patterns
were similar, with .50% of patients having unstable angina.
Although the majority of patients in both registries had
multivessel disease, the proportion was 10% higher in the
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
DCA 5 directional coronary atherectomy
MI 5 myocardial infarction
NACI 5 New Approaches to Coronary
Intervention
NHLBI 5 National Heart, Lung, and Blood
Institute
PTCA 5 percutaneous transluminal coronary
angioplasty
ROTA 5 rotational atherectomy
STRESS 5 Stress Restenosis Study
TEC 5 transluminal extraction catheter
TLR 5 target lesion revascularization
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NACI registry. Mean left ventricular ejection fraction was 3%
higher in the PTCA II registry. Although most baseline
features were similar among the five common sites and the
overall population in both registries, more patients from the
common sites had multivessel disease.
Characteristics of attempted lesions. As shown in Table 2,
slightly more patients in the PTCA II registry underwent
multivessel and multilesion angioplasty. In contrast, vein grafts
were attempted 10 times more in the NACI registry patients.
Although single, discrete lesions were more commonly treated
in the NACI registry, eccentric lesions and lesions containing
thrombus or calcium were also reported more frequently.
These variations may have reflected a closer scrutiny in
evaluating patients for specific devices in the NACI registry.
New device angioplasty created a larger lumen (final stenosis
diameter 32.8% in PTCA II vs. 18.9% in NACI) and therefore
had a higher lesion success rate.
Outcome. The angiographic success rate was 75% in
PTCA II registry patients and 86% in the NACI registry
patients (Table 3). The incidence of in-hospital major
complications (death, Q wave MI or CABG) was lower and
procedural success rate higher in the NACI registry. Subse-
quent CABG was more common in the PTCA registry,
whereas repeat percutaneous intervention was more com-
Table 1. Characteristics of Patients by Study Period
All Sites Common Sites*
PTCA II
(n 5 2,311)
NACI
(n 5 1,985)
PTCA II
(n 5 1,024)
NACI
(n 5 453)
Mean age (yr)† 58.2 63.5 58.2 63.0
Age $65 yr† 27.2% 48.6% 27.3% 45.9%
Male† 74.3% 70.2% 72.6% 67.5%
Median time from chest pain
(mo)†
6.0% 12.9% 7.0% 11.4%
Previous CABG† 11.5% 37.5% 11.3% 37.5%
Hx of MI 43.6% 44.7% 40.6% 45.7%
Hx of CHF† 5.6% 14.3% 4.9% 15.7%
Severe, concomitant disease† 5.8% 13.6% 5.8% 13.6%
Inoperable/high risk† 8.1% 20.7% 5.1% 14.2%
Hx of diabetes† 13.4% 20.9% 13.8% 20.2%
Hx of hypertension† 45.7% 52.7% 42.6% 51.4%
Hx of hypercholesterolemia
.250 mg/100 ml 33.3% — 35.9% —
.240 mg/100 ml — 56.1% — 49.7%
Smoking†
Present 30.2% 18.4% 33.3% 20.5%
Past 40.2% 43.7% 37.2% 41.3%
Never 29.5% 37.9% 29.5% 38.2%
Angina‡
None 3.5% 6.5% 3.6% 7.5%
Stable 42.5% 30.0% 28.6% 23.0%
Unstable 54.0% 57.5% 67.8% 58.5%
Only with MI 0 6.0% N/A 11.0%
Primary reason for revasc†
Angina 89.5% 83.9% 89.5% 79.9%
Silent ischemia 2.8% 4.3% 2.5% 2.9%
Acute MI 5.5% 7.3% 6.6% 11.0%
Other 2.2% 4.5% 1.4% 6.2%
Vessel disease†
Single 47.9% 38.1% 44.2% 34.9%
Double 31.8% 26.6% 32.9% 26.9%
Triple 20.3% 35.3% 22.9% 38.2%
LMCA stenosis $50%† 1.7% 9.8% 1.6% 11.3%
Average LVEF† 58.4% 55.2% 60.4% 56.1%
*Medical College of Virginia, Mayo Clinic, Emory University, Miami Heart Institute and Montreal Heart Institute.
†p , 0.001 between PTCA II and NACI registries for all sites. ‡Testing for angina status between the two registries was
not performed because of different categories in the two registries. Data are percent of patients, unless otherwise
indicated. CABG 5 coronary artery bypass graft surgery; CHF 5 congestive heart failure; Hx 5 history; LVEF 5 left
ventricular ejection fraction; LMCA 5 left main coronary artery; MI 5 myocardial infarction; N/A 5 not applicable;
NACI 5 New Approaches to Coronary Interventions registry; PTCA 5 Percutaneous Transluminal Coronary
Angioplasty registry; revasc 5 revascularization.
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mon in the NACI registry. These trends were similar among
common sites.
There was little difference in angina status at 1-year follow-
up. One-year physical activity levels favored the NACI registry;
59% of NACI and 46% of PTCA II registry patients reported
engaging in moderate or strenuous activity. However, similar
proportions were as limited as before the intervention (19%
for PTCA vs. 18% for NACI). Table 4 shows that angina-free
status was achieved with similar numbers of subsequent inter-
ventions. In patients without angina, no additional procedure
was performed in 73% in the PTCA registry and 68% in the
NACI registry, whereas subsequent percutaneous procedures
were performed in 14% and 20% and CABG in 13% and 12%,
respectively.
Risk-adjusted composite adverse events at 1 year. Table 5
shows the unadjusted and adjusted event rates at 1 year.
Although the cumulative 1-year mortality rate was twice as
high in the NACI registry (crude relative risk for mortality 1.96
for NACI registry patients vs. PTCA II registry patients), the
relative risk for mortality was no longer significant after risk
adjustment for other baseline characteristics associated with
mortality (Table 5). For the combined end point of death, MI
or any repeat revascularization, as well as the end point of
death, infarction or bypass surgery, the excess risk for NACI
registry patients remained significant even after adjustment.
Likewise, when TLR was adjusted for factors potentially
confounding comparison of the two registries (multiple-lesion
attempts during baseline procedure and routine follow-up
angiography), a significant excess risk remained in the NACI
registry.
The same analysis, restricted to patients from the five
common centers, revealed that after adjustment there was no
Table 2. Characteristics of Lesions (site assessment) by Study Period
All Sites Common Sites*
PTCA II
(n 5 3,611)
NACI
(n 5 2,313)
PTCA II
(n 5 1,620)
NACI
(n 5 555)
No. of vessels attempted†
1 79.2% 84.7% 80.7% 78.6%
2 18.2% 13.8% 17.0% 17.0%
3 2.6% 1.5% 2.3% 4.4%
No. of lesions attempted†
1 62.1% 69.5% 61.9% 60.5%
2 25.4% 21.3% 25.6% 24.9%
3 8.2% 6.8% 7.3% 9.0%
.3 4.3% 2.5% 5.2% 5.5%
Use of adjunctive balloon N/A 77.7% N/A 69.7%
Target vessel†
RCA 29.2% 24.3% 30.2% 27.0%
LMCA 0.4% 2.3% 0.2% 3.6%
LAD 45.3% 35.8% 44.9% 32.8%
LCx 21.7% 8.7% 21.6% 9.2%
CABG 3.4% 28.8% 3.1% 27.4%
Lesion morphology†
Single discrete 54.8% 63.5% 55.8% 68.6%
Multiple discrete 8.8% 5.1% 5.4% 5.1%
Diffuse 11.4% 16.8% 10.5% 10.6%
Tubular 19.2% 9.2% 23.2% 13.5%
Not visible 5.8% 5.5% 5.1% 2.2%
Thrombus† 8.6% 15.3% 10.2% 13.9%
Eccentric† 45.9% 71.9% 40.6% 75.8%
Calcium† 11.1% 24.7% 10.1% 23.8%
Supplies collateral‡ 8.4% 11.2% 6.0% 5.5%
Receives collateral† 20.3% 12.9% 19.3% 5.0%
Total occlusion§ 10.2% 8.6% 8.1% 4.5%
Lesion length
,10 mm N/A 71.5% N/A 80.9%
$10 mm N/A 28.5% N/A 19.1%
Mean % stenosis before Tx† 82.0% 78.9% 82.6% 73.7%
Mean final % stenosis† 32.8% 18.9% 35.4% 21.0%
*Medical College of Virginia, Mayo Clinic, Emory University, Miami Heart Institute and Montreal Heart Institute.
†p , 0.001, ‡p , 0.01 and §p , 0.05 between PTCA II and NACI registries for all sites. Data presented are percent of
patients. LAD 5 left anterior descending coronary artery; LCx 5 left circumflex artery; RCA 5 right coronary artery;
other abbreviations as in Table 1.
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significant excess mortality, but the end point of death or MI
was higher in the NACI registry (relative risk 1.67, 95%
confidence interval 1.16 to 2.38). However, the elevated TLR
risk in the NACI registry seen in the overall analysis was not
found in this subgroup.
TLR in patients with core laboratory readings. A sub-
sample of baseline angiographic films from six centers (658
NACI and 263 PTCA II films selected to provide a large
proportion of procedures involving vein graft angioplasty)
were analyzed in 1993 by the NACI core laboratory at Wash-
ington Hospital Center. In this subgroup of patients with core
laboratory readings, the adjusted relative risk of TLR for
PTCA II versus NACI was essentially the same (1.02).
TLR by device. Figure 1A shows rates of freedom from
TLR for PTCA II and NACI registry patients according to the
device used. TLR rates in patients treated with Palmaz-Schatz
stents and TEC were lower in the NACI cohort than in the
PTCA II cohort but were comparable in both registries for
patients treated with DCA. TLR rates in patients treated with
ROTA, laser or multiple new devices (combined because of
Table 3. In-Hospital Outcome and Follow-Up Events at 1 Year by Study Period
All Sites Common Sites*
PTCA II
(n 5 2,311)
NACI
(n 5 1,985)
PTCA II
(n 5 1,024)
NACI
(n 5 453)
Angiographic success 1,727 (74.7) 1,704 (85.8) 743 (72.6) 377 (83.2)
Major complications (death, Q
wave MI or CABG)
190 (8.2) 116 (5.8) 80 (7.8) 22 (4.9)
Procedural success 1,667 (72.1) 1,640 (82.6) 722 (70.5) 367 (81.0)
Death
In-hospital 23 (1.0) 36 (1.8) 7 (0.7) 4 (0.9)
Follow-up 48 (2.1) 81 (4.1) 22 (2.1) 19 (4.2)
1 year 71 (3.1) 117 (5.9) 29 (2.8) 23 (5.1)
Q wave MI†
In-hospital 77 (3.3) 29 (1.5) 32 (3.1) 8 (1.8)
Any MI
In-hospital 112 (4.8) 161 (8.1) 45 (4.4) 52 (11.5)
Follow-up 63 (2.7) 84 (4.2) 31 (3.0) 23 (5.1)
1 year 172 (7.4) 233 (11.7) 75 (7.3) 71 (15.7)
Any CABG
In-hospital 134 (5.8) 70 (3.5) 59 (5.7) 14 (3.1)
Follow-up 154 (6.7) 164 (8.3) 71 (6.9) 34 (7.5)
1 year 286 (12.4) 234 (11.8) 129 (12.6) 48 (10.6)
Repeat percutaneous
In-hospital 45 (1.9)† 47 (2.4) 17‡ (1.7) 10 (2.4)
Follow-up 424 (18.3) 428 (21.6) 197 (19.2) 96 (21.2)
1 year 468 (20.3) 468 (23.6) 213 (20.8) 105 (23.2)
*Medical College of Virginia, Mayo Clinic, Emory University, Miami Heart Institute and Montreal Heart Institute.
†Q wave myocardial infarction data at follow-up were not available for the PTCA registry. ‡Rate of in-hospital repeat
PTCA was reported if it was associated with abrupt closure. Data are presented as number (%) of patients. Abbreviations
as in Table 1.
Table 4. Most Aggressive Therapy* by Study Period for Patients Who Were Alive and Angina Free at
1 Year
All Sites Common Sites†
PTCA II
(n 5 1,391)
NACI
(n 5 1,221)
PTCA II
(n 5 485)
NACI
(n 5 267)
None or medication only 73.2% 67.9% 73.2% 68.1%
Repeat percutaneous
intervention only
14.2% 19.7% 13.2% 19.5%
CABG only 10.1% 9.0% 11.3% 9.0%
CABG and repeat percutaneous
intervention
2.6% 3.4% 2.3% 3.4%
*Level of therapy was classified hierarchically from least to most aggressive. †Medical College of Virginia, Mayo
Clinic, Emory University, Miami Heart Institute and Montreal Heart Institute. Date presented are percent of patients.
Abbreviations as in Table 1.
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the small numbers of each), however, were higher in the NACI
registry than in the PTCA II registry.
After adjustment for characteristics affecting the likelihood
of TLR, such as vein graft and multiple-lesion attempts and
routine (nonsymptom related) angiography during follow-up,
the lower risk of TLR in NACI registry patients treated with
TEC and Palmaz-Schatz stents (compared with the reference
category of PTCA II registry patients) was not statistically
significant. The increased risk of TLR in patients treated with
other single or multiple devices remained significant after
adjustment.
The previous analysis of TLR was also carried out for
procedures limited to native coronary arteries (2,210 for PTCA
II, 1,399 for NACI), because it is possible that the large
disparity in vein graft revascularizations between the two
registries may not have been sufficiently compensated for by
statistical adjustment. Figure 1B displays freedom from TLR
curves for this analysis. The rate of TLR was 21.5% in the
PTCA II registry and 28% in the NACI registry. As in the
overall analysis, the higher risk in the NACI registry patients
remained statistically significant after adjustment.
Discussion
In the mid to late 1980s, the limitations of balloon angio-
plasty became apparent. Some major problems were identified:
1) inability to cross lesions, especially chronic total occlusions;
2) inability to dilate resistant, elastic or diffuse lesions; 3)
difficulty in controlling or preventing arterial dissection, which
frequently led to abrupt closure; and 4) inability to control
restenosis (5). These shortcomings of PTCA led to a prolifer-
ation of new devices designed to address the problems. As
devices entered clinical testing, data were collected by the
sponsoring companies for Food and Drug Administration
submission, without balloon angioplasty control groups. To
facilitate a better understanding of the results with these new
devices, the NHLBI funded a new registry to provide common
definitions for baseline and outcome variables, ensure inde-
pendent data collection and core data center analysis and
compare the new data with similar data collected for balloon
angioplasty in the previous NHLBI registries.
It was hoped in the late 1980s and early 1990s that these
new devices might replace balloon angioplasty or at least fill
many of the clinical niches where standard balloon angioplasty
was thought to be inadequate (6). The lack of demonstrable
improvement in 1-year outcome with the new devices in the
NACI registry compared with PTCA alone was hardly ex-
pected in the optimistic days of the early 1990s. This failure is
particularly disappointing in light of the improved acute suc-
cess and lower residual stenosis seen in the NACI registry and
the benefits of new devices over PTCA observed in the random-
ized trials of stenting—Stent Restenosis Study (STRESS) (7),
the Belgian Netherlands Stent study (BENESTENT) (8) and the
Saphenous Vein De Novo (SAVED) (9) study—and DCA—the
Balloon Versus Optimal Atherectomy Trial (BOAT) (10) but not
the Coronary Angioplasty Versus Excisional Atherectomy Trial
(CAVEAT) (11) or the Canadian Coronary Atherectomy Trial
(CCAT) (12).
Randomized trials remain the reference standard for com-
paring new therapies. However, randomized trials seek rela-
tively homogeneous populations and thus have many clinical
and angiographic exclusions, whereas registries tend to offer a
Table 5. Rates and Relative Risks of Events at 1 Year: Comparison of the NHLBI PTCA II and
NACI Registries
Event
Event Rate (%) RR (95% CI) for NACI vs. PTCA II
PTCA II NACI Unadjusted Adjusted
Death* 3.1 5.9 1.96 (1.47–2.63) 1.00 (0.69–1.43)
Death/MI† 9.7 16.1 1.72 (1.45–2.04) 1.20 (0.98–1.49)
Death/MI/any repeat revasc‡ 33.5 41.6 1.32 (1.19–1.45) 1.23 (1.10–1.37)
Death/MI/CABG§ 18.6 24.6 1.37 (1.20–1.56) 1.25 (1.08–1.45)
Death/CABG\ 14.6 16.8 1.16 (1.00–1.35) 1.01 (0.85–1.20)
TLR¶ 21.5 24.2 1.11 (0.98–1.25) 1.28 (1.11–1.49)
*Cox model, adjusted for vein graft attempt (relative risk [RR] 1.1), age $65 years (RR 2.4), congestive heart failure
(CHF) (RR 2.99), severe, concomitant noncardiac disease (RR 1.8), high surgical risk (RR 3.0) and presence of thrombus (RR
1.6) in attempted lesion. †Cox model adjusted for vein graft attempt (RR 0.99), age $65 years (RR 1.2), CHF (RR 1.8), severe,
concomitant noncardiac disease (RR 1.3), high surgical risk (RR 1.6), unstable angina (RR 1.2), multivessel disease (RR 1.4),
presence of thrombus (RR 1.5) in attempted lesion, eccentric lesion (RR 1.2) and receives collateral vessels (RR 0.6). ‡Cox
model adjusted for vein graft attempt (RR 0.99), CHF (RR 1.2), diabetes (RR 1.2), unstable angina (RR 1.1), multivessel
disease (RR 1.3) and presence of calcium (RR 1.2) in attempted lesion. §Cox model adjusted for vein graft attempt (RR 1.3),
previous CABG (RR 0.6), CHF (RR 1.5), high surgical risk (RR 1.4), unstable angina (RR 1.3), multivessel disease (RR 1.5)
and presence of calcium (RR 1.3) in attempted lesion. \Cox model adjusted for vein graft attempt (RR 0.7), age $65 years (RR
1.2), CHF (RR 1.6), high surgical risk (RR 1.5), unstable angina (RR 1.2), multivessel disease (RR 1.5), multivessel attempt
(RR 0.6) presence of calcium (RR 1.4) and total occlusion (RR 1.3) in attempted lesion. ¶Cox model adjusted for vein graft
attempt (RR 0.6), smoking at baseline (RR 0.8), multilesion attempt (RR 1.1), presence of calcium (RR 1.2) in attempted
lesion, receives collateral vessels (RR 1.2) and routine follow-up angiograms (RR 0.7). CI 5 confidence interval; TLR 5 target
lesion revascularization, defined as repeat percutaneous intervention in target segment after hospital discharge or any coronary
artery bypass graft surgery (CABG).
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broader, more generalizable observation of device results. The
randomized trials have studied only a subset of patients. For
example, only 10% of the NACI registry patients treated with
Palmaz-Schatz stents would have met the inclusion criteria of
the STRESS study (7). Sawada et al. (13) reported 6-month
results for the majority of their patients whose baseline angio-
graphic characteristics fell outside the category of discrete
lesions studied in the STRESS and BENESTENT trials. For
patients with small vessels, long lesions, ostial disease, vein
grafts and restenotic lesions, the rate of restenosis at 6 months
ranged from 27% to 40% (13), twice that seen in “STRESS”-
like lesions. Colombo et al. (14,15) reported significantly
Figure 1. A, Freedom from TLR by study period and device used in
the NACI registry. B, Freedom from TLR by study period for
subgroups of patients with only native vessel attempted (2,210 for
PTCA II, 1,399 for NACI). Other device 5 Rotablator, lasers and
multiple devices; PSS 5 Palmaz-Schatz stent.
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higher restenosis rates for bifurcation and ostial lesions.
Kimura et al. (16) reported the 3-year follow-up data in a
diverse group of patients with native coronary artery stenting,
and Laham et al. (17) recently reported 4- to 6-year clinical
data in patients with both native and saphenous vein graft
stenting. Although these reports are encouraging regarding the
question of late stent restenosis and stent-related clinical
problems, the 3-year survival rate of 90.8% (16) is not superior
to that in the PTCA II registry or the PTCA arms of the
randomized Emory Angioplasty Surgery Trial (EAST) (18)
and Bypass Angioplasty Revascularization Investigation
(BARI) (19) in patients with multivessel disease. The de-
creased complication rates shown in the BENESTENT II trial
(20) may reflect improved techniques of balloon angioplasty
and stenting (high pressure balloon inflation after dilation) and
changes in anticoagulation regimens (aspirin and Ticlid) not
used in the NACI registry. Most of the devices other than
stents have been used for important niche applications, and
trials continue in an effort to define their best use. The lowest
TLR rate seen with TEC reflects its principal use in diffuse vein
graft disease, a subset frequently not undergoing reinterven-
tion, even if closure recurs.
Study limitations. Comparison of registries of different time
frames prevents definitive conclusions because device usage pat-
terns, clinical and angiographic characteristics and techniques
have changed. The techniques for using new devices have, in most
cases, undergone more prolonged evolution than the use of
balloon angioplasty. Compared with current catheters, the bal-
loons used in the PTCA II registry were larger in deflated profile
and capable of less pressure and utilized over the wire designs
introduced ;2 years before collection of the present series. The
mix of devices and techniques studied in the NACI registry
reflects practice from 1990 through 1994 and is not fully repre-
sentative of the mix of devices currently used. In the present
report, we focused on aggregation of the NACI registry devices
for the principal comparisons, and therefore the potential benefits
of one or two devices, such as the trend toward decreased TLR
associated with Palmaz-Schatz stents, were not addressed in
detail. Such individual device assessments will be the subject of
subsequent reports.
Although adjustment for risk factors and analysis using core
laboratory data supported our main findings, these analyses may
still have failed to fully correct for the differences in lesion and
patient characteristics between the two registries. There is also
the possibility that the site-reported TLR rates could have been
affected by follow-up factors other than the routine follow-up
angiography for which information was not available. Finally,
although this study of two relatively large groups had .90%
power to detect a $5% difference in overall TLR rates between
the two registries, a 10% difference would be required for the
same power in smaller device-specific subgroups (n 5 200).
Hence, it is possible that moderate device-specific improvements
in TLR rates were present but simply not detected as significant.
Conclusions. The present comparative study shows that
after adjustment for baseline patient risk profile, no overall
superiority of the new devices was seen in terms of patient
survival. Patients in the NACI registry did not have reduced
rates of MI or TLR compared with patients in the PTCA II
registry, even after adjusting for differences in patient and
lesion characteristics. Target lesion revascularization rates
varied by device, with NACI registry patients who underwent
Palmaz-Schatz stenting showing somewhat lower rates than
PTCA II registry patients. Although continued technologic and
procedural changes are significantly altering the early angio-
graphic results of intervention, the magnitude of their effect on
long-term clinical outcome remains unclear. Additional ran-
domized comparisons must be carried out when appropriately
targeted subsets can be defined. However, before we fully
embrace the across the board superiority of new technology
over established and more extensively observed interventions
(including medical and surgical), it will be prudent to examine,
through carefully controlled registries, the follow-up clinical
outcomes in the broad population of patients in whom these
technologies are presently being used.
References
1. Detre K, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary
angioplasty in 1985–1986 and 1977–1981: the National Heart, Lung, and
Blood Institute Registry. N Engl J Med 1988;318:265–70.
2. Steenkiste AR, Baim DS, Sipperly ME, Desvigne-Nickens P, Robertson T,
Detre K. The NACI Registry: an instrument for the evaluation of new
approaches to coronary intervention. Cathet Cardiovasc Diagn 1991;23:270–81.
3. Kaplan EL, Meier P. Nonparametric estimation from incomplete observa-
tion. J Am Stat Assoc 1958;53:457–81.
4. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc B
1972;74:187–220.
5. Baim DS, Detre KM, Kent K. Problems in the development of new devices
for coronary intervention: possible role for a multicenter registry. J Am Coll
Cardiol 1989;14:1389–92.
6. King SB. Role of new technology in balloon angioplasty. Circulation
1991;84:2574–9.
7. Fischman DL, Leon M, Baim DS, et al. A randomized comparison of
coronary stent placement and balloon angioplasty in the treatment of
coronary artery disease. N Engl J Med 1994;331:496–501.
8. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-
expandable-stent implantation with balloon angioplasty in patients with
coronary artery disease. N Engl J Med 1994;331:489–95.
9. Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared
with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med
1997;337:740–7.
10. Baim DS, Popma JJ, Sharma SK, et al. Final results in the Balloon vs
Optimal Atherectomy Trial (BOAT): 6 month angiography and 1 year
clinical follow-up [abstract]. Circulation 1996;94 Suppl I:I-436.
11. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional
atherectomy with coronary angioplasty in patients with coronary artery
disease. N Engl J Med 1993;329:221–7.
12. Adelman AG, Cohen EA, Kimball BP, et al. A comparison of directional
atherectomy with balloon angioplasty for lesions of the left anterior descend-
ing coronary artery. N Engl J Med 1993;329:228–33.
13. Sawada Y, Nosaka H, Kimura T, Nobuyoshi M. Initial and six month
outcome of Palmaz-Schatz stent implantation: STRESS/BENESTENT
equivalent versus non-equivalent lesions [abstract]. J Am Coll Cardiol
1996;27 Suppl:975A.
14. Colombo A, Gaglione A, Nakamura S, Finci L. “Kissing” stents for
bifurcational coronary lesion. Cathet Cardiovasc Diagn 1993;30:327–30.
15. Zampieri P, Colombo A, Almagor Y, Maiello L, Finci L. Results of coronary
stenting of ostial lesions. Am J Cardiol 1994;73:901–3.
16. Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation
of metallic coronary-artery stents. N Engl J Med 1996;334:561–6.
565JACC Vol. 31, No. 3 KING ET AL.
March 1, 1998:558–66 ONE-YEAR OUTCOMES IN NHLBI PTCA AND NACI
17. Laham RJ, Carrozza JP, Berger C, Cohen DJ, Kuntz RE, Baim DS.
Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late
clinical stent-related problems. J Am Coll Cardiol 1996;28:820–6.
18. King SB, Lembo NJ, Weintraub WS, et al. A randomized trial comparing
coronary angioplasty with coronary bypass surgery. N Engl J Med 1994;33:
1044–50.
19. The Bypass Angioplasty Revascularization Investigation (BARI) Investiga-
tors. Comparison of coronary bypass surgery with angioplasty in patients
with multivessel disease. N Engl J Med 1996;335:217–25.
20. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin-coated
Palmaz-Schatz stents in human coronary arteries: early outcome of the
BENESTENT-II pilot study. Circulation 1996;93:412–22.
566 KING ET AL. JACC Vol. 31, No. 3
ONE-YEAR OUTCOMES IN NHLBI PTCA AND NACI March 1, 1998:558–66
